BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 2, 2018--
Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that the underwriters of its previously announced
underwritten public offering of 5,500,000 shares of its common stock at
a price to the public of $32.00 per share have exercised in full their
option to purchase an additional 825,000 shares of common stock at the
public offering price, less underwriting discounts and commissions.
After giving effect to the closing on February 26, 2018, and the
additional closing completed today, Aimmune estimates gross proceeds
from the offering to be approximately $202.4 million.
BofA Merrill Lynch, Cantor Fitzgerald & Co. and Piper Jaffray & Co. are
acting as joint bookrunning managers for the offering. Credit Suisse and
RBC Capital Markets are also acting as bookrunning managers. Roth
Capital Partners and Wedbush PacGrow are acting as co-managers for the
A registration statement relating to the securities being sold in this
offering was filed with the Securities and Exchange Commission on
December 28, 2017, and was automatically declared effective upon filing.
The offering of these securities is being made only by means of a
prospectus, copies of which may be obtained from: BofA Merrill Lynch,
NC1-004-03, 200 North College Street, 3rd floor, Charlotte, NC
28255-0001, Attention: Prospectus Department, email: email@example.com;
or from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park
Avenue, 6th Floor, New York, NY 10022; email: firstname.lastname@example.org;
or from Piper Jaffray & Co., Attention: Prospectus Department, 800
Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at
800-747-3924 or email at email@example.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification of these securities under the securities laws of any such
state or jurisdiction.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for potentially life-threatening food
allergies. The company’s Characterized Oral Desensitization
ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels
of protection by desensitizing patients with defined, precise amounts of
key allergens. Aimmune’s first investigational biologic product using
CODIT™, AR101 for the treatment of peanut allergy, has received the
FDA’s Breakthrough Therapy Designation for the desensitization of
peanut-allergic patients 4–17 years of age and is currently being
evaluated in Phase 3 clinical trials.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180302005629/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.,